Tarsus Pharmaceuticals (TARS) Intangibles (2023 - 2026)

Tarsus Pharmaceuticals' Intangibles history runs 4 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• On a quarterly basis, Intangibles fell 11.87% year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a 11.87% decrease from a year earlier, with the FY2025 full-year figure at $7.4 million, down 11.53% from the prior year.
• Intangibles eased to $7.1 million in Q1 2026 per TARS's latest filing, from $7.4 million in the prior quarter.
• Across five years, Intangibles topped out at $8.6 million in Q3 2024 and bottomed at $3.7 million in Q2 2024.
• The 4-year median for Intangibles is $7.4 million (2025), against an average of $6.4 million.
• Across the five-year window, Intangibles surged 115.96% in 2024 and decreased 11.87% in 2026, its largest moves.
• Year by year, Intangibles stood at $3.9 million in 2023, then soared by 115.31% to $8.3 million in 2024, then slipped by 11.53% to $7.4 million in 2025, then retreated by 3.26% to $7.1 million in 2026.
• Per Business Quant, the three latest TARS Intangibles figures stand at $7.1 million (Q1 2026), $7.4 million (Q4 2025), and $7.6 million (Q3 2025).